Bolt Biotherapeutics Company Insiders

Bolt Biotherapeutics Management Team Effectiveness

The company has return on total asset (ROA) of (0.2941) % which means that it has lost $0.2941 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5804) %, meaning that it created substantial loss on money invested by shareholders. Bolt Biotherapeutics' management efficiency ratios could be used to measure how well Bolt Biotherapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.45 in 2024. Return On Capital Employed is likely to drop to -0.57 in 2024. Non Current Liabilities Total is likely to gain to about 46.8 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 16.1 M in 2024. Common Stock Shares Outstanding is likely to drop to about 35.4 M in 2024. Net Loss is likely to drop to about (83.3 M) in 2024

Bolt Biotherapeutics Workforce Comparison

Bolt Biotherapeutics Insider Trading

Bolt Biotherapeutics Notable Stakeholders

The success or failure of an entity such as Bolt Biotherapeutics often depends on how effective the management is. Bolt Biotherapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Bolt management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Bolt management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

Please note, the imprecision that can be found in Bolt Biotherapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Bolt Biotherapeutics. Check Bolt Biotherapeutics' Beneish M Score to see the likelihood of Bolt Biotherapeutics' management manipulating its earnings.

When running Bolt Biotherapeutics' price analysis, check to measure Bolt Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bolt Biotherapeutics is operating at the current time. Most of Bolt Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Bolt Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bolt Biotherapeutics' price. Additionally, you may evaluate how the addition of Bolt Biotherapeutics to your portfolios can decrease your overall portfolio volatility.